How do clinical pathways help in reducing the rising cost of healthcare? how do healthcare executives proceed in implementing clinical pathways in their respective systems in a way that assures buy-in from their stakeholders, maintaining patients’ access to life saving therapies, and contenting to bend the cost curve? I provide some suggestions to healthcare executives

During the 2016 American Society of Hematology (ASH) meeting, I was interviewed by OBR to offer an opinion on how payers are implementing clinical pathways in how they provide coverage to patients with hematologic malignancies. Pathways are not always welcome by physicians and healthcare providers and there is always a debate about their value. In

I was interviewed by OBR during the 2016 annual American Society of Hematology (ASH) meeting, and was asked about important CLL presentations that took place during that meeting. At the time, I was a VP and CMO at Cardinal Health Specialty Solutions.

During the 2016 American Society of Hematology (ASH) meeting, I was interviewed about how clinical pathways could be integrated as part of managing patients with chronic lymphocytic leukemia (CLL). Pathways are suggested to reduce variability in care but some oppose pathways as infringing on clinical decision-making. At the time of this OBR interview, I was